This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug

Core Viewpoint - Vir Biotechnology's stock surged by 29% due to excitement surrounding its prostate cancer drug candidate, VIR-5500, following a partnership with Astellas Pharma for co-development and co-commercialization [1] Company Developments - Vir Biotechnology has entered into an agreement with Astellas Pharma to co-develop and co-commercialize VIR-5500, which is its lead cancer drug candidate [1] - The collaboration with Astellas Pharma positions Vir Biotechnology to potentially become a significant player in the cancer drug market [1] Market Reaction - The stock market reacted positively to the news, indicating strong investor interest and confidence in the future prospects of Vir Biotechnology's cancer drug [1]